Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Evotec Receives First Milestone in Roche Biomarker Collaboration

Published: Thursday, April 24, 2014
Last Updated: Thursday, April 24, 2014
Bookmark and Share
Evotec AG announce the successful achievement of a milestone in its biomarker alliance with Roche.

The milestone was achieved on the decision by Roche to use a response prediction marker, identified using Evotec's Proteome Profiling platform, in an extended phase I oncology trial.

This is the first minor milestone achieved under the collaboration and licence agreement between Evotec and Roche, signed in 2011, which is part of the m4 Munich Biotech Cluster Personalized Medicine and Targeted Therapiesinitiative funded by the German Federal Ministry of Education and Research. Under the initial three-year term, Evotec and Roche conduct biomarker discovery and validation programmes for patient stratification in targeted cancer therapy. Evotec is eligible for further success-based payments upon clinical companion diagnostics development.

Dr Mario Polywka, Chief Operating Officer of Evotec AG, commented: "We are delighted with receiving this milestone and the first validation of our novel biomarker concept with Roche. I would like to thank everyone involved in the project to date for the fantastic science they have developed and for the hard work and determination to see it succeed in a clinical setting."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec and Debiopharm Group™ to Collaborate
Innovative partnership based on Evotec’s Target X projects.
Wednesday, April 02, 2014
Evotec and Merck KGaA to Collaborate on Neurological Disease Target
Evotec to apply integrated drug discovery expertise and technologies to identify interesting small molecules for the selected target.
Wednesday, November 24, 2010
Evotec Announces the Successful Completion of the First Phase I Study with EVT 401
The double-blind, placebo controlled study showed that the compound was safe and well tolerated without any serious adverse events.
Friday, July 10, 2009
Evotec Presents its Fragment Screening Technology at Two Key Conferences
Presentations will be given at Screening, MedChem and ADMET Europe and at the Molecular Medicine Tri-Conference.
Thursday, February 19, 2009
Evotec Announces Phase I Initiation with P2X7 Antagonist
P2X7 receptor antagonism may provide a novel approach to the treatment of rheumatoid arthritis and other inflammatory conditions.
Friday, October 10, 2008
Evotec Extends Ongoing Collaboration with CHDI Worth up to US$ 37 Million
Three-year extension for integrated drug discovery support in the search of novel drug candidates for the treatment of Huntington Disease.
Tuesday, February 19, 2008
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
NIH Commits $6.7 M to Advance DNA, RNA Sequencing Technology
"Can you believe they make DNA sequencers the size of staplers?" asked Meni Wanunu, Ph.D. "Ideas that were crazy twenty years ago are now happening!"
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Curcumin Shows Promise as Cancer Treatment
When delivered at the correct circadian phase, curcumin demonstrates sustained toxicity in cancer cells and should be considered for use in patient care.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos